Health insurance giant UnitedHealth Group reached a 52-week high of $404.14 during Wednesday's trading session, continuing its recent strong performance. Data shows the stock has gained approximately 30% over the past month and about 21% year-to-date.

The primary catalyst for this rise was the company's first-quarter earnings report released in late April. The report indicated UnitedHealth achieved quarterly revenue of $111.7 billion, a 2% year-over-year increase, with adjusted earnings per share of $7.23, significantly surpassing market expectations of $6.76. Additionally, the company raised its full-year 2026 adjusted earnings per share guidance to above $18.25.

A key highlight from the earnings report was the medical loss ratio, which improved substantially to 83.9% from 88.9% in the fourth quarter of last year. This enhancement is largely attributed to the company's strategic decision to proactively reduce 1.3 million Medicare Advantage members to protect profit margins. The operating margin for the related business segment also increased from 6.2% to 6.6%.

Following the earnings release, several investment banks upgraded their ratings and price targets for UnitedHealth. The current consensus rating on Wall Street for the stock is "Moderate Buy."

The company also announced it will eliminate prior authorization requirements for 30% of medical services, a move viewed by the market as a positive signal for improving customer experience. As of Wednesday's close, the company's market capitalization was approximately $344 billion, with a dividend yield of about 2.3%.